Industry Day for FDA Contact Center Optimization
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FOOD AND DRUG ADMINISTRATION
Contract Value
Not provided
Codes & Classification
Solicitation Number
FDA-RFI-2026-131159
NAICS
-
Classification Code
-
Additional Details
The U.S. Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a Special Notice regarding an upcoming Industry Day focused on the optimization of the FDA Contact Center. This initiative, identified by procurement number FDA-RFI-2026-131159, is designed to engage industry partners in discussions and information sharing that will inform future procurement activities related to enhancing the FDA’s contact center operations.
**Purpose and Scope:**
The primary objective of this Industry Day is to provide a forum for potential contractors to gain insight into the FDA’s vision for optimizing its contact center. The event aims to foster dialogue between the FDA and industry stakeholders, clarify requirements, and gather feedback on the draft Statement of Objectives (SOO). The intended outcome is to ensure that the FDA’s future procurement strategy is well-informed by industry best practices and capabilities, ultimately leading to improved efficiency, customer service, and technological advancement within the FDA Contact Center.
**Key Requirements and Deliverables:**
While the full scope of work will be detailed in future solicitation documents, the current notice highlights several important elements:
- A draft SOO has been made available for industry review, and vendors are encouraged to submit questions in advance (limited to two per vendor) by the specified deadline.
- The FDA is seeking input on the draft SOO to refine its requirements and ensure alignment with industry standards and innovations.
- The event will include presentations, Q&A sessions, and opportunities for direct engagement with FDA representatives.
**Event Logistics and Participation:**
- The Industry Day is scheduled for Monday, February 23, 2026, in Silver Spring, Maryland.
- All interested vendors must RSVP by February 17, 2026, by emailing the designated government points of contact. Each organization may send up to two representatives.
- Business formal attire is required, and vendors are responsible for their own lodging.
- Supplementary materials, including parking information, visitor guidelines, and security requirements, are provided as attachments to the notice.
- A coffee service will be available on-site.
**Contracting Entity and Contact Information:**
- Contracting Entity: U.S. Food and Drug Administration (FDA), a federal agency under the Department of Health and Human Services.
- Place of Performance: Silver Spring, Maryland, United States.
- Primary Contact: Lilibeth Deato ([email protected])
- Secondary Contact: Min Jie Zeng ([email protected])
- Additional contacts for questions regarding the SOO include Kenya Thomas and Shailesh Shah.
**Procurement Type and Special Considerations:**
- This notice is classified as a Special Notice and is not a solicitation for proposals at this stage.
- There are no set-aside requirements specified; the opportunity is open to all interested parties.
- The FDA prefers that questions regarding the draft SOO be submitted in advance, with a clear subject line as specified in the notice.
**Additional Information:**
- The notice and all related updates, including meeting minutes, slide decks, and logistical details, are posted on SAM.gov (Opportunity ID: f4119181880c465b9d61d1ef1a363a25).
- Contractors are encouraged to monitor SAM.gov for future announcements and to review all attached materials for comprehensive event preparation.
**Summary for Contractors:**
This Industry Day represents a valuable opportunity for contractors specializing in contact center operations, customer service optimization, and related technologies to engage directly with the FDA, understand its strategic objectives, and influence the development of future procurement requirements. Interested parties should ensure timely registration, review all provided materials, and prepare thoughtful questions or feedback on the draft SOO to maximize their participation and alignment with the FDA’s needs.
Documents6